Rezolute (RZLT) Stock Price, News & Analysis

Company Overview

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $3.86 to $4.23
• 50-Day Range: $3.07 to $4.58
• 52-Week Range: $1.07 to $11.46
• Volume: 1.31 million shs
• Average Volume: 1.81 million shs
• Market Capitalization: $385.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.75
• Consensus Rating: Moderate Buy

Rezolute Stock Analysis - MarketRank™

Rezolute scored higher than 67% of companies evaluated by MarketBeat, and ranked 282nd out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Rezolute has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Rezolute has a consensus price target of $8.75, representing about 118.8% upside from its current price of $4.00.

Amount of Analyst Coverage

Rezolute has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rezolute are expected to grow in the coming year, from ($0.69) to ($0.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rezolute is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rezolute is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rezolute has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.72% of the float of Rezolute has been sold short.

Short Interest Ratio / Days to Cover

Rezolute has a short interest ratio ("days to cover") of 11.91, which indicates bearish sentiment.

Change versus previous month

Short interest in Rezolute has recently decreased by 5.94%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rezolute does not currently pay a dividend.

Dividend Growth

Rezolute does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.37

News Sentiment

Rezolute has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Rezolute this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for RZLT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

8 people have added Rezolute to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rezolute insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.78% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 6/13/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RZLT
• CIK: 1509261
• Web: www.rezolutebio.com
• Phone: (650) 206-4507
• Fax: N/A
• Employees: 40
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Rezolute: $8.75
• High Price Target: $20.00
• Low Price Target: $2.00
• Potential Upside/Downside: +118.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -58.82%
• Return on Assets: -54.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.84
• Quick Ratio: 15.84

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.86 per share
• Price / Book: 2.15

Miscellaneous

• Outstanding Shares: 96,290,000
• Free Float: 82,060,000
• Market Cap: $385.16 million
• Optionable: Optionable
• Beta: 0.68